PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,899,590 | -4.2% | 485,645 | +25.1% | 0.03% | 0.0% |
| Q2 2023 | $15,559,061 | +19.5% | 388,297 | +21.7% | 0.03% | +7.1% |
| Q1 2023 | $13,024,962 | +169.1% | 319,161 | +154.6% | 0.03% | +154.5% |
| Q4 2022 | $4,840,033 | +111.7% | 125,357 | +191.8% | 0.01% | +120.0% |
| Q3 2022 | $2,286,000 | +113.8% | 42,961 | +134.5% | 0.01% | +150.0% |
| Q2 2022 | $1,069,000 | -91.3% | 18,323 | -91.1% | 0.00% | -91.3% |
| Q4 2021 | $12,357,000 | +1376.3% | 205,322 | +1274.2% | 0.02% | +666.7% |
| Q3 2021 | $837,000 | -61.0% | 14,941 | -51.2% | 0.00% | -70.0% |
| Q1 2021 | $2,147,000 | +141.0% | 30,624 | +55.7% | 0.01% | +66.7% |
| Q4 2019 | $891,000 | -91.4% | 19,673 | -92.8% | 0.01% | -92.7% |
| Q3 2019 | $10,400,000 | +2726.1% | 273,162 | +2441.3% | 0.08% | +2633.3% |
| Q3 2016 | $368,000 | -83.5% | 10,749 | -80.2% | 0.00% | -88.9% |
| Q3 2015 | $2,229,000 | – | 54,226 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |